Our first-in-class isotope selective modulator, KLS1, is a small molecule PARP1 inhibitor.
With current focus on evaluating KLS-1 in oncology indications, we are planning to expand our pipeline to neurological and metabolic diseases based upon the broad therapeutic potential of isotopically-modified zinc.
| Indication | Discovery | Preclinical | Phase 1 | IND-Appl | Phase 2 | Phase 3 | |
|---|---|---|---|---|---|---|---|
Oncology | |||||||
| Cutaneous Melanoma * | |||||
| Discovery | Preclinical | IND-Enabl | Phase 1 | Phase 2 | Phase 3 |
| Prostate Cancer * | |||||
| Discovery | Preclinical | Phase 1 | IND-Appl | Phase 2 | Phase 3 |
| Pancreatic Cancer * | |||||
| Discovery | Preclinical | Phase 1 | IND-Appl | Phase 2 | Phase 3 |
| Chronic Lymphocytic Leukemia * | |||||
| Discovery | Preclinical | Phase 1 | IND-Appl | Phase 2 | Phase 3 |
| B-16 Melanoma (Co-therapy w. Paclitaxel) ** | |||||
| Discovery | Preclinical | Phase 1 | IND-Appl | Phase 2 | Phase 3 |
| B-16 Melanoma (Co-therapy w. Dacarbazine) ** | |||||
| Discovery | Preclinical | Phase 1 | IND-Appl | Phase 2 | Phase 3 |
| B-16 Melanoma (Co-therapy w. Vinorelbine) ** | |||||
| Discovery | Preclinical | Phase 1 | IND-Appl | Phase 2 | Phase 3 |
| B-16 Melanoma (Co-therapy w. Doxorubicin) ** | |||||
| Discovery | Preclinical | Phase 1 | IND-Appl | Phase 2 | Phase 3 |
| B-16 Melanoma (Co-therapy w. Cisplatin) ** | |||||
| Discovery | Preclinical | Phase 1 | IND-Appl | Phase 2 | Phase 3 |
| A-549 Lung Cancer ** | |||||
| Discovery | Preclinical | Phase 1 | IND-Appl | Phase 2 | Phase 3 |
| HL-60 Leukemia ** | |||||
| Discovery | Preclinical | Phase 1 | IND-Appl | Phase 2 | Phase 3 |
| SK-N-SH Neuroblastoma ** | |||||
| Discovery | Preclinical | Phase 1 | IND-Appl | Phase 2 | Phase 3 |
| Merkel Cell Carcinoma (w. Pembrolizumab) ** | |||||
| Discovery | Preclinical | Phase 1 | IND-Appl | Phase 2 | Phase 3 |
| Cutaneous Melanoma (w. Pembrolizumab) ** | |||||
| Discovery | Preclinical | Phase 1 | IND-Appl | Phase 2 | Phase 3 |
Next Milestone
* Patient recruitment in UA for Phase 1-2a. IND filing in the U.S. for Phase 2b.
** Entering into collaboration agreement with a Big Pharma company.
Pipeline Products
Learn more about our product development, research, and progress in developing our breakthrough therapies.
Evaluating KLS-1 monotherapy in patients with chronic lymphocytic leukemia and malignant neoplasms
-
Evaluating KLS1 as monotherapy in healthy volunteers
-
Evaluating KLS1 in combinations with doxorubicin in patients with acute lymphocytic leukemia
-
Metastatic Breast Cancer
KLS1 combination therapy with Paclitaxel
-
-
Ovarian Cancer
KLS1 combination therapy with Dacarbazine and Cisplatin
-
-
-
Cutaneous Melanoma
Combination therapy with Pembrolizumab and KLS1
-
Hodgkin Lymphoma
Combination therapy with Doxorubicin and KLS1
-
Merkel Cell Carcinoma
Combination therapy with Avelumab and KLS1